STOCK TITAN

Alector to Participate in Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alector (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract neurodegeneration, has announced its participation in three upcoming healthcare investor conferences in March 2025.

The company will deliver corporate presentations at the following events:

  • TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET
  • Leerink Partners Global Biopharma Conference in Miami on Tuesday, March 11, 2025, at 8:40 a.m. ET
  • Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025, at 2:00 p.m. ET

Webcasts of all presentations will be available on the "Events & Presentations" page within the Investors section of the Alector website. Replay access will remain available for 90 days following each presentation.

Alector (Nasdaq: ALEC), una società biotecnologica in fase avanzata di sviluppo clinico focalizzata sulla creazione di terapie per contrastare la neurodegenerazione, ha annunciato la sua partecipazione a tre prossime conferenze per investitori nel settore sanitario nel marzo 2025.

La società presenterà presentazioni aziendali nei seguenti eventi:

  • TD Cowen 45ª Conferenza Annuale sulla Salute a Boston martedì 4 marzo 2025, alle 9:10 ET
  • Leerink Partners Conferenza Globale Biopharma a Miami martedì 11 marzo 2025, alle 8:40 ET
  • Stifel 2025 Forum Virtuale CNS martedì 18 marzo 2025, alle 14:00 ET

Le registrazioni di tutte le presentazioni saranno disponibili nella pagina

Positive
  • Alector (ALEC) is maintaining visibility with investors through participation in multiple high-profile healthcare conferences
  • The company's focus on neurodegeneration represents a significant market opportunity in an area of high unmet medical need
  • Alector's status as a late-stage clinical biotechnology company suggests potential near-term catalysts or data readouts
Negative
  • The press release contains no updates on clinical progress or pipeline developments
  • No financial information or business updates were provided in the announcement
  • Investor conference presentations alone may not significantly impact stock performance without accompanying clinical or business news

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

  • TD Cowen 45th Annual Health Care Conference (Boston, Massachusetts)
    • Tuesday, March 4, 2025, at 9:10 a.m. ET, corporate presentation
  • Leerink Partners Global Biopharma Conference (Miami, Florida)
    • Tuesday, March 11, 2025, at 8:40 a.m. ET, corporate presentation
  • Stifel 2025 Virtual CNS Forum
    • Tuesday, March 18, 2025, at 2:00 p.m. ET, corporate presentation

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically-validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer’s disease, Parkinson's disease, and Lewy body dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts:
Alector
Katie Hogan
(202) 549-0557
katie.hogan@alector.com

Argot Partners (media)
David Rosen
(212) 600-1494
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com


FAQ

When is Alector (ALEC) presenting at the TD Cowen Health Care Conference in March 2025?

Alector (ALEC) will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET.

How long will Alector (ALEC) conference presentation replays be available on their website?

Replays of Alector's (ALEC) conference presentations will be available on the company website for 90 days following each presentation date.

Which investor conferences will Alector (ALEC) attend in March 2025?

In March 2025, Alector (ALEC) will participate in three investor conferences: TD Cowen 45th Annual Health Care Conference (March 4), Leerink Partners Global Biopharma Conference (March 11), and Stifel 2025 Virtual CNS Forum (March 18).

What is Alector's (ALEC) main therapeutic focus according to their March 2025 conference announcement?

According to their conference announcement, Alector (ALEC) is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration.

Where can investors access Alector's (ALEC) March 2025 conference presentations?

Investors can access webcasts of Alector's (ALEC) March 2025 conference presentations on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com.

Alector

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

164.48M
85.75M
9.97%
96.39%
5.7%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO